NEW YORK – In 2024, firms in the sepsis testing space made big moves to begin or expand the commercialization of tests that could help reduce the time-to-results, while many also secured funding to ...
NEW YORK — Laboratory-developed tests, FDA actions, the JP Morgan Healthcare Conference, and Roche — perhaps not surprisingly these subjects dominated the attention of 360Dx readers in 2024. Reader ...
NEW YORK – For clinical labs, 2024 will most likely be remembered as the year the US Food and Drug Administration finally made good on its decades-old promise — or threat, depending on your point of ...
The company consolidated its instrument lineup with its newer Atellica instruments and is phasing out support for Advia and Dimension branded analyzers through 2030.
NEW YORK – Diagnostics firm Fujirebio and drugmaker Eisai said Monday that they have entered a memorandum of understanding for research into and use of blood-based biomarkers for neurodegenerative ...